Bubs Australia (BUB) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
12 Jun, 2026Executive summary
Achieved FY25 revenue of $102.5M, surpassing the $100M target with 29% year-over-year growth, driven by strong demand in key markets, especially the USA.
Achieved inaugural statutory after-tax profit of $5.5M for FY25, reversing a $21.0M loss in FY24.
Underlying EBITDA turned positive at $0.6M, a turnaround from a $20.3M loss in FY24, reflecting improved margin and cost control.
Delivered positive operating cash flow of $6.1M and net assets of $42.5M, supported by disciplined working capital management.
New CEO with 30+ years in consumer products and dairy, focused on people, partners, and business performance.
Financial highlights
FY25 revenue reached $102.5M, up 29% year-over-year, with the USA contributing 52% of total revenue.
Gross profit margin at 48%, with gross profit rising to $49.1M.
Underlying EBITDA positive at $0.6M; baseline EBITDA $5.5M, a turnaround from $20.3M loss in FY24.
Net operating cash inflow of $6.1M, a significant improvement from prior year.
Cash and cash equivalents at $17.4M, with all borrowings repaid and $10M facility available.
Outlook and guidance
Strategy update planned for late November 2025 to map out full potential and resource alignment.
Expectation to rebuild inventories in early FY26 to support continued USA demand growth, impacting operating cash flow in the first half.
Gross margin expected to normalize at 40%-45% as tariffs and potential air freight are absorbed.
Continued investment in marketing, especially in the U.S., to drive brand equity and customer acquisition.
Continued focus on growth in the USA and China, with expansion in Japan and Vietnam.
Latest events from Bubs Australia
- Revenue up 33–34% to AUD 80m, with strong US/China growth and FY25 EBITDA breakeven targeted.BUB
H2 202412 Jun 2026 - First-ever half-year net profit and 23% revenue growth, led by US and China, with risks ahead.BUB
H1 202512 Jun 2026 - US-driven 14% revenue growth, 48% US surge, strong margin, but cash and regulatory risks persist.BUB
H1 202612 Jun 2026 - FY26 revenue expected at $105–115 million, with US expansion and strong liquidity supporting growth.BUB
Trading update28 May 2026 - FY26 revenue guidance raised to AUD 120–125m, targeting 22–27% growth and strong EBITDA.BUB
Status update8 Apr 2026 - Strong growth, margin gains, and US/China expansion set up for FY25 profitability.BUB
AGM 202413 Jan 2026 - Strong FY25 growth, global expansion, and strategic focus on FDA and China drive outlook.BUB
AGM 202520 Nov 2025 - Net revenue up 30% to $25.6m, EBITDA positive, and $22.9m in liquidity at quarter end.BUB
Q1 2026 TU30 Oct 2025 - FY25 saw 29% revenue growth, positive EBITDA, and strong US and China market performance.BUB
Q4 2025 TU28 Jul 2025